Akebia Therapeut Stock Price, News & Analysis

On July 5, 2022, Akebia Therapeutics (Nasdaq: AKBA) announced the grant of stock options to two newly-hired employees, totaling 4,000 shares. These options were awarded to incentivize employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price of $0.35, which matches the closing stock price on the grant date. The options vest over four years, with 25% vesting on the first anniversary and the remainder vesting quarterly, contingent on continued service. Akebia focuses on therapeutics for kidney disease.

Akebia Therapeutics (Nasdaq: AKBA) announced the termination of its collaboration with Otsuka Pharmaceutical regarding vadadustat, with a settlement fee of $55 million to be received by Akebia. This decision allows Akebia to regain rights to vadadustat in multiple regions, including the U.S., Europe, China, and others. The company aims to pursue regulatory approval for vadadustat, especially after receiving a Complete Response Letter from the FDA. Akebia's CEO expressed optimism about the product's potential for treating anemia in chronic kidney disease patients.

Akebia Therapeutics, Inc. (Nasdaq: AKBA) will be presenting at the Jefferies Healthcare Conference on June 9, 2022, at 10:30 a.m. ET. CEO John Butler will represent the company, which focuses on improving the lives of those affected by kidney disease. The conference is scheduled for June 8-10, 2022, in New York. Investors can access a live webcast of the presentation on the company’s website, with a replay available for 90 days after. Akebia, established in 2007 and based in Cambridge, Massachusetts, is dedicated to developing therapeutics for kidney disease.

Akebia Therapeutics (Nasdaq: AKBA) announced the grant of stock options to three new employees totaling 14,000 shares on May 31, 2022. The options, which have an exercise price of $0.37 per share, align with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting quarterly, contingent on continued employment. Akebia, based in Cambridge, Massachusetts, focuses on biopharmaceutical solutions for kidney disease.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company dedicated to improving the lives of those affected by kidney disease, will have CEO John Butler participate in a fireside chat at the H.C. Wainwright Global Investment Conference, scheduled for May 23–26, 2022. An audio replay of the chat will be accessible through Akebia's investor relations webpage starting on May 24 for approximately 90 days. Founded in 2007 and based in Cambridge, Massachusetts, Akebia focuses on developing and commercializing therapeutics for kidney disease.

Akebia Therapeutics (AKBA) reported a 36% increase in net Auryxia revenue, totaling $41.4 million in Q1 2022. Total revenue reached $61.7 million, up from $52.3 million a year earlier. The company provided 2022 revenue guidance for Auryxia of $165 million to $170 million. Despite a Complete Response Letter from the FDA regarding vadadustat, Akebia aims to focus on Auryxia's commercial success and explore earlier-stage assets. The cash position stands at $174.6 million.

Akebia Therapeutics (Nasdaq: AKBA) plans to release its first-quarter financial results for 2022 on May 9, 2022, after market close. The company will hold a conference call at 4:30 p.m. ET to discuss these results and provide a business update. Participants can join the call via phone or listen live on Akebia's website. A replay will be available shortly after the call concludes, lasting until May 15, 2022. Akebia focuses on developing therapeutics for individuals affected by kidney disease.

On April 6, 2022, Akebia Therapeutics (Nasdaq: AKBA) announced its participation in the National Kidney Foundation Spring Clinical Meetings 2022 in Boston, scheduled for April 6-10, 2022. The company will present three significant posters focusing on real-world healthcare costs, adherence to phosphate binders, and thrombotic events in dialysis-dependent patients. Notably, Vadadustat, an investigational drug for chronic kidney disease anemia, received a complete response letter from the FDA on March 29, 2022, while still under review by the European Medicines Agency.

On April 4, 2022, Akebia Therapeutics (Nasdaq: AKBA) announced the grant of stock options to nine newly-hired employees, totaling 53,000 shares. Each option has an exercise price of $0.72, matching the closing stock price on the grant date. These options vest over four years, with 25% vesting on the first anniversary and the remainder quarterly, contingent on continued employment. The grant complies with Nasdaq Listing Rule 5635(c)(4) and aims to strengthen employee retention and incentivize performance.